Private Eye

Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

CEO and CFO buying at Microbix Biosystems (T:MBX)

Updated Friday Oct 20, 2017 02:18 AM EDT

Cameron Lionel Groome, CEO and Director, acquired 333,334 Common Shares on a direct ownership basis at a price of $0.300 through a prospectus or prospectus exempt offering on October 18th, 2017. The insider also acquired 166,668 Warrants with an exercise price of $0.360 for 3 years. This represents a $100,000 investment into the company's shares and an account share holdings change of greater than 100%.

On the same terms, James Stuart Currie, CFO, acquired 50,000 Common Shares and 25,000 Warrants on a direct ownership basis. This represents a $15,000 investment into the company's shares and an account share holdings change of greater than 100%.

Microbix Biosystems is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Microbix Biosystems Inc. is a life science company and manufacturer of viral and bacterial antigens and reagents for the diagnostics industry. The Company develops biological products and technologies. The Company operates in two segments: the development, manufacturing and distribution of cell-based products and technology, and the provision of facility, technical and production personnel for contract research and development. The Company's Virology Products (Virology) business manufactures and sells cell culture-based biological products. The Company's pipeline of technologies and products include Kinlytic, which is a thrombolytic drug with various applications, including the treatment of life-threatening blood clots, and LumiSort, which is a semen sexing technology for the livestock industries. It operates in three geographical areas, including North America, Europe and in other foreign countries. It owns and operates a Virology manufacturing facility at Mississauga, Ontario.

INK Edge Outlook

6 months ago
1 year ago
Mostly Sunny
The INK Edge Outlook is a quantitative process that ranks a stock based on our V.I.P. criteria.
View outlooks on all Canadian listed stocks at
Two-week free trial for first time users.
Go to Microbix Biosystems Inc. (MBX)'s company page

Comment On!

Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to (via Easy Blurb).

Comment On!

No Comments


Search (past week) for $MBX.CA

  • No tweets found